Legacy Capital Group California, Inc. Cue Biopharma, Inc. Transaction History
Legacy Capital Group California, Inc.
- $301 Billion
- Q3 2024
A detailed history of Legacy Capital Group California, Inc. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Legacy Capital Group California, Inc. holds 10,000 shares of CUE stock, worth $10,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$10,500
Previous $12.4 Million
38.94%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CUE
# of Institutions
52Shares Held
14.1MCall Options Held
14.4KPut Options Held
2.6K-
Bleichroeder LP New York, NY5MShares$5.25 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$2.52 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$2.13 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$794,5720.0% of portfolio
-
Geode Capital Management, LLC Boston, MA509KShares$534,2680.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $37.2M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...